NCT05732181View on ClinicalTrials.gov

The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation

NACompletedINTERVENTIONAL
Enrollment

154

Participants

Timeline

Start Date

May 9, 2017

Primary Completion Date

April 30, 2018

Study Completion Date

April 30, 2018

Conditions
Liver CancerPost Ablation Syndrome
Interventions
DRUG

The skin lidocaine patch.

The skin patch is applied before RFA while admission and is changed every day till discharge. Pain severity is evaluated by visual analogue scale using a 10-point scale recorded before RFA and after the procedure.

DRUG

Placebo

patch without drugs

Trial Locations (1)

704

National Cheng Kung University Hospital, Tainan City

All Listed Sponsors
lead

National Cheng-Kung University Hospital

OTHER

NCT05732181 - The Role of 5% Lidocaine Patches in the Pain Control of Hepatocellular Carcinoma Patients Receiving Radiofrequency Ablation | Biotech Hunter | Biotech Hunter